

GLAXOSMITHKLINE PLC  
Form 6-K/A  
January 15, 2015

FORM 6-K/A

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 2015

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

This announcement replaces the original announcement released on 5 January 2015.

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc (the 'Company').

On 31 December 2014, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary Shares and ADSs in the Company through the annual reinvestment of dividends paid throughout 2014; calculated using an average price of £13.84 per Ordinary Share and \$42.91 per ADS:

Non-Executive Director	Ordinary Shares	No. of ADSs
Sir Christopher Gent	6,385.452	
Prof Sir Roy Anderson	1,003.260	
Dr Stephanie Burns		886.521
Stacey Cartwright	256.043	
Lynn Elsenhans		308.422
Judy Lewent		208.857
Sir Deryck Maughan		2,255.597
Dr Daniel Podolsky		1,613.970
Tom de Swaan	1,389.497	
Jing Ulrich		98.139
Hans Wijers	76.661	

The Company and the Non-Executive Directors were informed of these allocations on 5 January 2015.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte  
Company Secretary

15 January 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 15, 2015

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc